A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.

5 d), including the downregulation of TGFβ signalling (nearly significant in SW1353, FDR = 0.055) ( Fig. 5 e), the upregulation of mTORC1 signalling ( Fig. 5 f) or the activation of unfold protein response signalling.

also in 3,287 other papers